Updates on management of lipids beyond LDL-c and (new-onset) diabetes in preventive cardiology - PACE-CME

Updates on management of lipids beyond LDLc and newonset diabetes in preventive cardiology

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

What we can learn from registry data to improve lipid goal attainment
What we can learn from registry data to improve lipid goal attainment
Hyperlipidemia
What we can learn from registry data to improve lipid goal attainment
- Kausik Ray, MBChB, MD, MPhil
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
AHA 2024
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Effect of decision support system on early optimization of lipid-lowering therapy
Effect of decision support system on early optimization of lipid-lowering therapy
AHA 2024
Effect of decision support system on early optimization of lipid-lowering therapy
- Kausik Ray, MBChB, MD, MPhil
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
MinuteCE®
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
0.75 program credits
- Ulrich Laufs, MD, PhD
0.75 program credits